{"id":"sy-5007","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL1989853","moleculeType":"Small molecule","molecularWeight":"348.40"},"_fixedAt":"2026-03-30T17:56:49.554529","_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, SY-5007 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This makes it a potential treatment for type 2 diabetes.","oneSentence":"SY-5007 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:53:44.635Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"_fixedFields":["pubmed(3)"],"trialDetails":[{"nctId":"NCT07469982","phase":"PHASE1","title":"A Phase I Study of SY-9453 in Patients With Advanced Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Shouyao Holdings (Beijing) Co. LTD","startDate":"2026-02","conditions":"Advanced or Metastatic Solid Tumors With Homozygous MTAP Deletion","enrollment":122},{"nctId":"NCT06352190","phase":"PHASE1","title":"A Study to Evaluate the Mass Balance of [14C] SY-5007 in Healthy Adult Male Subjects in China","status":"UNKNOWN","sponsor":"Shouyao Holdings (Beijing) Co. LTD","startDate":"2024-05-01","conditions":"Healthy Subjects","enrollment":8},{"nctId":"NCT06332053","phase":"PHASE1","title":"A Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of SY-5007 in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Shouyao Holdings (Beijing) Co. LTD","startDate":"2024-04-01","conditions":"Healthy Subjects","enrollment":28},{"nctId":"NCT06325761","phase":"PHASE1","title":"A Study to Evaluate the Food Effects on Pharmacokinetics of SY-5007 Tablets in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Shouyao Holdings (Beijing) Co. LTD","startDate":"2024-04-01","conditions":"Health Subjects","enrollment":28},{"nctId":"NCT06031558","phase":"PHASE3","title":"Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC","status":"RECRUITING","sponsor":"Shouyao Holdings (Beijing) Co. LTD","startDate":"2023-06-20","conditions":"Non-Small Cell Lung Cancer","enrollment":120},{"nctId":"NCT05278364","phase":"PHASE1, PHASE2","title":"Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor","status":"UNKNOWN","sponsor":"Shouyao Holdings (Beijing) Co. LTD","startDate":"2021-04-23","conditions":"Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Solid Tumor","enrollment":184}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"recentPublications":[{"date":"2025","pmid":"41278287","title":"Review and analysis of clinical trials of selective RET inhibitors for the treatment of thyroid cancer.","journal":"Frontiers in oncology"},{"date":"2025 Oct","pmid":"40913959","title":"Overcoming resistance in RET-altered cancers through rational inhibitor design and combination therapies.","journal":"Bioorganic chemistry"},{"date":"2024 Nov 4","pmid":"39489747","title":"First-in-human, phase 1 dose-escalation and dose-expansion study of a RET inhibitor SY-5007 in patients with advanced RET-altered solid tumors.","journal":"Signal transduction and targeted therapy"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SY-5007 Capsule","SY-5007 tablets"],"phase":"phase_3","status":"active","brandName":"SY-5007","genericName":"SY-5007","companyName":"Shouyao Holdings (Beijing) Co. LTD","companyId":"shouyao-holdings-beijing-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SY-5007 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}